Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management

Panelists discuss how the combination therapy of cretostimogene plus pembrolizumab offers a promising new approach for managing BCG-unresponsive non-muscle-invasive bladder cancer, highlighting its potential benefits and the implications of its FDA Breakthrough Therapy Designation for clinical practice.

EP: 1.Prevalence and Staging of Newly Diagnosed Bladder Cancer

EP: 2.Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC

EP: 3.Recurrence and BCG Resistance in High-Risk NMIBC

EP: 4.Therapies Beyond BCG: FDA-Approved and Emerging Options

EP: 5.Cretostimogene, Grenadenorepvec, and Pembrolizumab for BCG-Unresponsive NMIBC: Overview of ASCO 2024 Data

EP: 6.CORE-001 Trial Participation and Eligibility Criteria

EP: 7.Comparing Cretostimogene and BCG Administration Methods

EP: 8.Results of the CORE-001 Trial: 24-Month Complete Response Rate and Duration of Response

EP: 9.Safety Outcomes and Duration of Response in Combination Therapy vs. Monotherapy for BCG UR CIS +/- Papillary Disease

Now Viewing

EP: 10.Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management

EP: 11.Evaluating Cretostimogene: BOND-003 and PIVOT-006 Trial Results

EP: 12.Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination Therapy

Video content above is prompted by the following questions:

• In your opinion, what does cretostimogene plus pembrolizumab combination therapy offer to the management of BCG-unresponsive NMIBC?
• Cretostimogene plus pembrolizumab received an FDA Breakthrough Therapy Designation in May 2023. What is important for physicians to know or understand about this designation?

Related Videos

Related Content

Advertisement

January 16th 2025

Anktiva targets expanded indication in US and global approvals in EU and UK

Hannah Clarke

The planned sBLA will seek approval of Anktiva for patients with BCG-unresponsive NMIBC in the papillary indication.

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

January 14th 2025

Bladder tumor-focused adaptive radiotherapy shows feasibility in phase 2 trial

Hannah Clarke

“In this phase 2 study, an image-guided adaptive strategy enabled radiotherapy dose escalation to over 86% of patients’ bladder tumors without significant increase in toxicity,” wrote the authors.

December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff

“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.

January 10th 2025

CREST: Sasanlimab hits primary end point of EFS for NMIBC

Benjamin P. Saylor

Results from CREST will be presented at an upcoming medical conference.

January 10th 2025

FDA greenlights phase 2 SURF302 trial of TYRA-300 in NMIBC

Hannah Clarke

"We expect to initiate patient dosing in the second quarter of this year, with initial three-month [complete response] data to follow," says Doug Warner.

Related Content

Advertisement

January 16th 2025

Anktiva targets expanded indication in US and global approvals in EU and UK

Hannah Clarke

The planned sBLA will seek approval of Anktiva for patients with BCG-unresponsive NMIBC in the papillary indication.

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

January 14th 2025

Bladder tumor-focused adaptive radiotherapy shows feasibility in phase 2 trial

Hannah Clarke

“In this phase 2 study, an image-guided adaptive strategy enabled radiotherapy dose escalation to over 86% of patients’ bladder tumors without significant increase in toxicity,” wrote the authors.

December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff

“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.

January 10th 2025

CREST: Sasanlimab hits primary end point of EFS for NMIBC

Benjamin P. Saylor

Results from CREST will be presented at an upcoming medical conference.

January 10th 2025

FDA greenlights phase 2 SURF302 trial of TYRA-300 in NMIBC

Hannah Clarke

"We expect to initiate patient dosing in the second quarter of this year, with initial three-month [complete response] data to follow," says Doug Warner.